Sareum Regulatory News (SAR)

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Movement in share price

Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, notes the movement in its share price on 27 July 2016.

An article was published by the Institute of Cancer Research ("ICR") in Molecular Cancer Therapeutics earlier this month, which came to Sareum's attention yesterday. The article refers to the evaluation of a Sareum/ICR developed CHK1 inhibitor, CCT244747, combined with radiotherapy in head and neck squamous cell carcinoma. Although the CHK1 inhibitor had beneficial effects, Sareum concluded, following consultation with its nominated adviser, that the information was not price sensitive as the ICR had previously published in 2013 on the benefits of a Sareum/ICR developed CHK1 inhibitor combined with radiotherapy, and as the CHK1 inhibitor used in the latest evaluation was not the CHK1 inhibitor, CCT245737, currently undergoing clinical trials co-funded by Sareum.

For further information:

Notes for editors:

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes a programme in Phase I clinical trials and another undergoing pre-clinical IND-enabling studies.

SKIL(R) (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and autoimmune disease research programmes. SKIL(R) can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

Checkpoint Kinase 1 (CHK1) and CCT245737: Most chemotherapies work by damaging the DNA of rapidly dividing cells. In response, cancer cells can activate an enzyme, known as CHK1, which delays cell division and gives cancer cells an opportunity to repair their damaged DNA. This enables the cancer cells to survive the DNA damage and become resistant to the cell-killing effects of chemotherapeutic agents.

Studies have shown that oral dosing of CCT245737, the CHK1 clinical development candidate being funded by the Sareum / CRT Pioneer Fund co-development partnership, and other lead series compounds can boost the activity of relevant chemotherapies in in vivo models of lung, pancreatic and colon cancers. Furthermore, strong efficacy has been demonstrated by these inhibitors when dosed as a single anti-cancer agent in several in vivo models of cancers that undergo replication stress, including certain types of AML (Acute Myeloid Leukaemia) lymphoma and paediatric neuroblastoma.

A detailed description of CCT245737 was published in the high-impact journal, Oncotarget, in July 2015 and in the Journal of Medicinal Chemistry in May 2016.